BARDA To Fund Pediatric Development Of Cempra’s Solithromycin
This article was originally published in The Pink Sheet Daily
Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.
You may also be interested in...
The antibiotic showed promising results in a late-stage study of the oral formulation, setting the company up as a potential target for acquirers and partnering opportunities – though for now it is signaling its intent to go it alone.
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.